Significant Accounting Policies (Tables)

9 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Schedule of the impact of the immaterial correction of an error

The condensed consolidated financial statements as of and for the three and nine months ended March 31, 2022 have been adjusted as shown in the following tables.

	Three Months Ended
	March 31, 2022
	As Previously
	Reported		Adjustment		As Adjusted
	(in thousands)
Statement of Operation data
Gain on derivative warrant liabilities	$	211	$	(218)	$	(7)
Total other (expense) income (1)	$	348	$	(218)	$	130
Loss before income tax	$	(53,073)	$	(218)	$	(53,291)
Net loss	$	(53,073)	$	(218)	$	(53,291)
Basic and diluted net loss per common share	$	(35.80)	$	(0.10)	$	(35.90)
Statement of Stockholders' Equity data
Issuance of common stock, net of issuance cost	$	7,034	$	(3,178)	$	3,856
Net loss by segment
Rx Segment	$	(52,311)	$	(218)	$	(52,529)
Consumer Health Segment		(762)		—		(762)
Consolidated net loss	$	(53,073)	$	(218)	$	(53,291)

(1)  Includes reclassification of gain or loss from fair value of contingent consideration. See Prior Period Reclassification in Note 1 – Nature of Business, Financial Condition, Basis of Presentation.

	Nine Months Ended
	March 31, 2022
	As Previously
	Reported		Adjustment		As Adjusted
	(in thousands)
Statement of Operation data
Gain on derivative warrant liabilities	$	211	$	(218)	$	(7)
Total other (expense) income (1)	$	384	$	(218)	$	166
Loss before income tax	$	(92,582)	$	(218)	$	(92,800)
Net loss	$	(92,472)	$	(218)	$	(92,690)
Basic and diluted net loss per common share	$	(68.00)	$	(0.13)	$	(68.13)
Statement of Cash Flow data
Net loss	$	(92,472)	$	(218)	$	(92,690)
Gain on derivative warrant liabilities	$	(211)	$	218	$	7
Net loss by segment
Rx Segment	$	(88,359)	$	(218)	$	(88,577)
Consumer Health Segment		(4,113)		—		(4,113)
Consolidated net loss	$	(92,472)	$	(218)	$	(92,690)

(1)  Includes reclassification of gain or loss from fair value of contingent consideration. See Prior Period Reclassification in Note 1 – Nature of Business, Financial Condition, Basis of Presentation.

	As of March 31, 2022
	As Previously
	Reported		Adjustment		As Adjusted
	(in thousands)
Statement of Stockholders' Equity data
Additional paid-in capital	$	331,915	$	(3,178)	$	328,737
Accumulated deficit		(270,771)		(218)		(270,989)
Total stockholders’ equity	$	61,144	$	(3,396)	$	57,748

The consolidated balance sheet and the consolidated statement of stockholders’ equity as of June 30, 2022 have been adjusted as shown in the table below.

	As of June 30, 2022
	As Previously
	Reported		Adjustment		As Adjusted
	(in thousands)
Derivative warrant liabilities	$	—	$	1,796	$	1,796
Total liabilities	$	91,531	$	1,784	$	93,315
Additional paid-in capital	$	334,560	$	(3,174)	$	331,386
Accumulated deficit	$	(288,472)	$	1,394	$	(287,078)
Total stockholders’ equity	$	46,092	$	(1,784)	$	44,308